| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver | 16 | 2025 | 1860 | 2.940 |
Why?
|
| Hepatocytes | 12 | 2025 | 245 | 2.390 |
Why?
|
| Gene Editing | 7 | 2025 | 213 | 2.260 |
Why?
|
| CRISPR-Cas Systems | 6 | 2024 | 298 | 2.020 |
Why?
|
| Chimera | 5 | 2018 | 87 | 1.980 |
Why?
|
| Hepatitis B virus | 6 | 2020 | 140 | 1.150 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 2 | 2025 | 115 | 1.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2018 | 142 | 1.060 |
Why?
|
| Genetic Therapy | 5 | 2024 | 737 | 1.030 |
Why?
|
| Disease Models, Animal | 14 | 2025 | 4760 | 1.020 |
Why?
|
| Transaminases | 1 | 2025 | 36 | 0.950 |
Why?
|
| Dependovirus | 4 | 2024 | 153 | 0.940 |
Why?
|
| Glutaryl-CoA Dehydrogenase | 1 | 2023 | 4 | 0.830 |
Why?
|
| Heterografts | 5 | 2020 | 201 | 0.810 |
Why?
|
| Copper | 6 | 2005 | 75 | 0.770 |
Why?
|
| Lysine | 1 | 2023 | 207 | 0.760 |
Why?
|
| Tyrosinemias | 2 | 2024 | 7 | 0.740 |
Why?
|
| Mice | 29 | 2025 | 18936 | 0.740 |
Why?
|
| Argininosuccinate Lyase | 2 | 2018 | 65 | 0.710 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2018 | 54 | 0.690 |
Why?
|
| Animals | 37 | 2025 | 36222 | 0.680 |
Why?
|
| Mitochondria | 1 | 2025 | 755 | 0.650 |
Why?
|
| Xenobiotics | 1 | 2018 | 28 | 0.590 |
Why?
|
| Inactivation, Metabolic | 1 | 2018 | 32 | 0.590 |
Why?
|
| Cation Transport Proteins | 4 | 2005 | 101 | 0.570 |
Why?
|
| Adenosine Triphosphatases | 5 | 2005 | 202 | 0.560 |
Why?
|
| Atazanavir Sulfate | 1 | 2017 | 6 | 0.550 |
Why?
|
| Quinazolines | 1 | 2017 | 185 | 0.500 |
Why?
|
| Receptors, LDL | 2 | 2017 | 103 | 0.490 |
Why?
|
| Mice, Knockout | 8 | 2024 | 3979 | 0.480 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2016 | 197 | 0.480 |
Why?
|
| Hydrolases | 4 | 2025 | 61 | 0.470 |
Why?
|
| Hepatitis B | 2 | 2020 | 172 | 0.430 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2015 | 111 | 0.430 |
Why?
|
| Monocytes | 1 | 2016 | 346 | 0.430 |
Why?
|
| Killer Cells, Natural | 1 | 2016 | 357 | 0.420 |
Why?
|
| Antiviral Agents | 2 | 2018 | 824 | 0.410 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 2 | 2022 | 13 | 0.380 |
Why?
|
| Drug Discovery | 1 | 2013 | 180 | 0.370 |
Why?
|
| Transplantation Chimera | 2 | 2015 | 44 | 0.360 |
Why?
|
| Hepatitis B, Chronic | 3 | 2018 | 86 | 0.360 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 276 | 0.340 |
Why?
|
| Gene Targeting | 2 | 2025 | 185 | 0.340 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1415 | 0.320 |
Why?
|
| Mice, Inbred Strains | 4 | 2017 | 317 | 0.310 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1770 | 0.310 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2001 | 805 | 0.280 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 2 | 2020 | 73 | 0.280 |
Why?
|
| Oxidoreductases | 2 | 2018 | 103 | 0.270 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2023 | 1005 | 0.260 |
Why?
|
| Humans | 33 | 2025 | 133811 | 0.260 |
Why?
|
| Immune Tolerance | 1 | 2007 | 149 | 0.260 |
Why?
|
| Depressive Disorder, Major | 2 | 2022 | 472 | 0.250 |
Why?
|
| Enzyme Inhibitors | 2 | 2016 | 606 | 0.250 |
Why?
|
| Hep G2 Cells | 4 | 2020 | 98 | 0.250 |
Why?
|
| Hepatitis C | 1 | 2010 | 387 | 0.240 |
Why?
|
| Carrier Proteins | 2 | 2001 | 1075 | 0.240 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2025 | 82 | 0.230 |
Why?
|
| Genes, Essential | 1 | 2025 | 43 | 0.230 |
Why?
|
| Enterococcus | 2 | 2001 | 31 | 0.230 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 312 | 0.220 |
Why?
|
| Menkes Kinky Hair Syndrome | 2 | 2001 | 5 | 0.220 |
Why?
|
| Microsomes, Liver | 2 | 2021 | 100 | 0.210 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2023 | 14 | 0.200 |
Why?
|
| Simplexvirus | 1 | 2003 | 107 | 0.190 |
Why?
|
| Hepatitis | 1 | 2003 | 57 | 0.190 |
Why?
|
| Models, Animal | 2 | 2018 | 483 | 0.190 |
Why?
|
| Molybdenum | 1 | 2001 | 15 | 0.190 |
Why?
|
| Nitrobenzoates | 2 | 2024 | 7 | 0.190 |
Why?
|
| Cyclohexanones | 2 | 2024 | 19 | 0.180 |
Why?
|
| Hepatoblastoma | 1 | 2024 | 183 | 0.180 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2001 | 35 | 0.180 |
Why?
|
| Plasmids | 2 | 2018 | 531 | 0.180 |
Why?
|
| Transfection | 2 | 2020 | 1096 | 0.170 |
Why?
|
| Liver Regeneration | 1 | 2000 | 41 | 0.170 |
Why?
|
| Carbohydrates | 1 | 2020 | 38 | 0.170 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2020 | 39 | 0.170 |
Why?
|
| Blood Vessels | 1 | 2020 | 108 | 0.160 |
Why?
|
| Epidermal Growth Factor | 1 | 2000 | 123 | 0.160 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 399 | 0.160 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2000 | 88 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 2 | 2018 | 259 | 0.160 |
Why?
|
| Tissue Scaffolds | 1 | 2020 | 85 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 4823 | 0.160 |
Why?
|
| Hepatectomy | 1 | 2000 | 124 | 0.160 |
Why?
|
| Trans-Activators | 2 | 2020 | 836 | 0.160 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 202 | 0.150 |
Why?
|
| Oocytes | 1 | 2001 | 302 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2020 | 2559 | 0.150 |
Why?
|
| Multiprotein Complexes | 1 | 2020 | 219 | 0.150 |
Why?
|
| Copper-transporting ATPases | 3 | 2005 | 26 | 0.150 |
Why?
|
| Tissue Engineering | 1 | 2020 | 180 | 0.150 |
Why?
|
| Argininosuccinic Aciduria | 1 | 2018 | 56 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 429 | 0.140 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2017 | 60 | 0.140 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 265 | 0.140 |
Why?
|
| Cytochromes | 1 | 2017 | 7 | 0.140 |
Why?
|
| Fetal Stem Cells | 1 | 2017 | 5 | 0.140 |
Why?
|
| Virion | 1 | 2018 | 151 | 0.140 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 238 | 0.140 |
Why?
|
| Phenotype | 2 | 2018 | 4593 | 0.140 |
Why?
|
| Recombinational DNA Repair | 1 | 2017 | 19 | 0.140 |
Why?
|
| HIV Protease Inhibitors | 1 | 2017 | 47 | 0.140 |
Why?
|
| HIV-1 | 1 | 2020 | 489 | 0.120 |
Why?
|
| Mutagenesis | 1 | 2017 | 358 | 0.120 |
Why?
|
| Amniotic Fluid | 1 | 2017 | 154 | 0.120 |
Why?
|
| Liver Transplantation | 2 | 2015 | 1124 | 0.120 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2020 | 408 | 0.120 |
Why?
|
| Gene Transfer Techniques | 1 | 2017 | 362 | 0.120 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 139 | 0.120 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 4 | 1 | 2015 | 47 | 0.120 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 88 | 0.120 |
Why?
|
| Viremia | 1 | 2015 | 134 | 0.120 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2015 | 56 | 0.110 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2017 | 231 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2018 | 539 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 504 | 0.110 |
Why?
|
| Lipoproteins | 1 | 2015 | 192 | 0.110 |
Why?
|
| Genome | 1 | 2017 | 529 | 0.110 |
Why?
|
| Female | 8 | 2025 | 71840 | 0.110 |
Why?
|
| RNA Interference | 1 | 2015 | 547 | 0.100 |
Why?
|
| Exons | 1 | 2016 | 839 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 2 | 2007 | 402 | 0.100 |
Why?
|
| Tuberculosis | 1 | 2020 | 553 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 63 | 0.100 |
Why?
|
| Cell Line | 2 | 2016 | 2861 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2018 | 750 | 0.100 |
Why?
|
| Duloxetine Hydrochloride | 2 | 2022 | 14 | 0.100 |
Why?
|
| Myocytes, Cardiac | 1 | 2017 | 644 | 0.090 |
Why?
|
| Male | 7 | 2025 | 65939 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 2177 | 0.090 |
Why?
|
| Serotonin | 2 | 2022 | 223 | 0.090 |
Why?
|
| Rats | 3 | 2020 | 3851 | 0.090 |
Why?
|
| Genotype | 1 | 2017 | 2819 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2003 | 3172 | 0.080 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 710 | 0.080 |
Why?
|
| Embryonic Stem Cells | 1 | 2010 | 177 | 0.080 |
Why?
|
| Hypertension | 1 | 2018 | 1403 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2015 | 1630 | 0.070 |
Why?
|
| Stem Cells | 1 | 2013 | 748 | 0.070 |
Why?
|
| Hepacivirus | 1 | 2010 | 273 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2017 | 2029 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2020 | 614 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1853 | 0.070 |
Why?
|
| HIV Infections | 1 | 2020 | 2075 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 2136 | 0.070 |
Why?
|
| Mutation | 2 | 2017 | 6350 | 0.060 |
Why?
|
| Rats, Inbred LEC | 1 | 2005 | 1 | 0.060 |
Why?
|
| Electrophoresis | 1 | 2005 | 52 | 0.060 |
Why?
|
| 4-Hydroxyphenylpyruvate Dioxygenase | 1 | 2024 | 1 | 0.060 |
Why?
|
| Electroporation | 1 | 2024 | 34 | 0.060 |
Why?
|
| Hydroxamic Acids | 1 | 2024 | 65 | 0.050 |
Why?
|
| Rats, Wistar | 1 | 2005 | 398 | 0.050 |
Why?
|
| Child | 4 | 2018 | 25882 | 0.050 |
Why?
|
| Organ Size | 1 | 2005 | 464 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 1013 | 0.050 |
Why?
|
| Transgenes | 1 | 2025 | 344 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2024 | 91 | 0.050 |
Why?
|
| Carcinogens | 1 | 2023 | 160 | 0.050 |
Why?
|
| Vincristine | 1 | 2024 | 196 | 0.050 |
Why?
|
| Acyclovir | 1 | 2003 | 47 | 0.050 |
Why?
|
| Central Nervous System Agents | 1 | 2022 | 16 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2022 | 35 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2024 | 168 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2022 | 49 | 0.050 |
Why?
|
| Kinetics | 2 | 2001 | 1323 | 0.050 |
Why?
|
| Herpes Simplex | 1 | 2003 | 57 | 0.050 |
Why?
|
| Propranolol | 1 | 2022 | 121 | 0.050 |
Why?
|
| Colectomy | 1 | 2003 | 84 | 0.050 |
Why?
|
| Gastric Mucosa | 1 | 2005 | 400 | 0.050 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2003 | 73 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2001 | 89 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2018 | 3144 | 0.050 |
Why?
|
| Silver | 1 | 2001 | 30 | 0.050 |
Why?
|
| Artificial Gene Fusion | 1 | 2001 | 12 | 0.040 |
Why?
|
| DNA Repair | 1 | 2025 | 638 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 2524 | 0.040 |
Why?
|
| Oxygen | 1 | 2005 | 578 | 0.040 |
Why?
|
| Xenopus laevis | 1 | 2001 | 129 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2001 | 256 | 0.040 |
Why?
|
| Quinolines | 1 | 2001 | 115 | 0.040 |
Why?
|
| Liver Cirrhosis, Experimental | 1 | 2000 | 5 | 0.040 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2020 | 15 | 0.040 |
Why?
|
| Luminescent Proteins | 1 | 2001 | 167 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2023 | 362 | 0.040 |
Why?
|
| Marmota | 1 | 2020 | 3 | 0.040 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 5 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2000 | 73 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2003 | 213 | 0.040 |
Why?
|
| Norepinephrine | 1 | 2020 | 174 | 0.040 |
Why?
|
| Guinea Pigs | 1 | 2020 | 169 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2005 | 791 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2001 | 334 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 366 | 0.040 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 70 | 0.040 |
Why?
|
| Hydrogels | 1 | 2020 | 109 | 0.040 |
Why?
|
| Reoperation | 1 | 2003 | 853 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 310 | 0.040 |
Why?
|
| Perfusion | 1 | 2020 | 210 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2001 | 483 | 0.040 |
Why?
|
| Cell Division | 1 | 2000 | 766 | 0.040 |
Why?
|
| Rabbits | 1 | 2020 | 710 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2020 | 513 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 605 | 0.040 |
Why?
|
| Coinfection | 1 | 2020 | 182 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2001 | 1147 | 0.030 |
Why?
|
| Urea Cycle Disorders, Inborn | 1 | 2018 | 85 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 824 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2017 | 30 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2017 | 45 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2001 | 1707 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 318 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2000 | 1303 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1318 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2017 | 94 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2017 | 117 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2017 | 170 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2017 | 146 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 1733 | 0.030 |
Why?
|
| Virus Replication | 1 | 2020 | 634 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 471 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 157 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2015 | 13 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2001 | 924 | 0.030 |
Why?
|
| DNA, Circular | 1 | 2015 | 18 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1853 | 0.030 |
Why?
|
| Cellular Reprogramming | 1 | 2017 | 130 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 504 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2018 | 487 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2015 | 470 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 1532 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 234 | 0.030 |
Why?
|
| Time Factors | 1 | 2005 | 6554 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2015 | 497 | 0.030 |
Why?
|
| Homeostasis | 1 | 1998 | 748 | 0.030 |
Why?
|
| Viral Load | 1 | 2015 | 411 | 0.030 |
Why?
|
| Lipids | 1 | 2017 | 565 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 1106 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 721 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2015 | 562 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3047 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2018 | 870 | 0.020 |
Why?
|
| Base Sequence | 1 | 2017 | 3169 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2018 | 1411 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 910 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2015 | 966 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 964 | 0.020 |
Why?
|
| Computational Biology | 1 | 2015 | 890 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 2216 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3799 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2010 | 624 | 0.020 |
Why?
|
| Neoplasms | 1 | 2020 | 3035 | 0.010 |
Why?
|
| Pregnancy | 1 | 2017 | 7599 | 0.010 |
Why?
|
| United States | 1 | 2020 | 11760 | 0.010 |
Why?
|
| Surface Plasmon Resonance | 1 | 2001 | 52 | 0.010 |
Why?
|
| Adult | 1 | 2003 | 31823 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2001 | 174 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 20610 | 0.010 |
Why?
|